Conventional Antibiotic
Preclinical
Conventional Antibiotic is one of 5 therapeutic programs targeting Enterobacteriaceae Infections. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Enterobacteriaceae Infections
#DrugCompanyPhaseTrials
1Maxipime
PfizerApproved
Merrem
BB. Braun Medical Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Conventional Antibiotic
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Enterobacteriaceae Infections1 trial
An Study on the Efficacy of Probiotic Preparations as Adjunctive Therapy for Decolonization of Carbapenem-Resistant Enterobacterales
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Preclinical·NCT07707869·20 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Conventional Antibiotic. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]